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ABSTRACT  
Human endogenous retroviruses (HERVs) have recently caught increased attention as a potential internal 
trigger to sensitize tumor cells to immunotherapies. HERVs are remnants of retroviral germline infections 
that resulted in chromosomal integration into all the cells of the progeny. Today, HERVs constitute ∼8% of 
the human genome, but most elements are highly degenerated, under strict epigenetic regulation, and 
rarely expressed in healthy tissues. However, cancer cells are specifically prone to reactivate the expression 
of HERV elements due to epigenetic dysregulation that accumulate during malignant transformation and 
when using epigenetic therapies. HERV expression can induce an interferon response due to induction of 
the viral defense pathway, so-called ‘viral mimicry’. By mimicking viral infections, HERVs could function as 
an ‘intrinsic adjuvant’, possibly sensitizing cancer cells to immunological recognition. Furthermore, 
translated HERV elements may in themselves form a valuable pool of tumor-associated antigens. Epitopes 
derived from HERVs have been recognized by cytotoxic CD8+ T cells, leading to cancer cell recognition. The 
combination of ‘viral mimicry’ and T-cell recognition could provide a powerful combination with existing 
immune stimulatory therapies, such as checkpoint inhibition. This combination is currently being evaluated 
in clinical trials in a large number of cancers. 
KEYWORDS 
Cancer immunotherapy, HERV, Combination therapy, Immune checkpoint inhibitors, DNA 
methyltransferase inhibitors, Tumor-associated antigens 
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KEY MESSAGE 
Alleviating the epigenetic repression of HERVs using DNA methyltransferase inhibitors may sensitize cancer 
cells to immunological recognition through a ‘viral mimicry’ process and through direct recognition of 
HERV-derived T-cell epitopes. Consequently the combination of immune checkpoint inhibitor therapy and 
epigenetic modulation is currently intensively evaluated. 
INTRODUCTION 
Human endogenous retroviruses (HERVs) constitute ∼8% of the human genome, distributed in ∼700,000 
elements [1]. They are remnants of retroviral germline infections that resulted in chromosomal integration 
into all the cells of the progeny, but their viral replication is defective in the present-day human genome 
[2]. Most HERVs are highly degenerated through evolutionary pressure due to accumulation of mutations 
or homologous recombination between proviral long terminal repeats (LTRs) [3]. Although most HERVs are 
under strict epigenetic repression and the protein coding capacity is limited, some HERVs are transcribed 
due to the strong promoter activity of the flanking LTRs [1, 3]. The fixation of HERVs in the human genome 
is not the end of the immunological conflict between the host and retrovirus. HERVs’ retroviral origin, 
together with the fact that they constitute a large amount of the human genome, makes them interesting 
from an immunological perspective [3]. Replication intermediates from HERVs can induce an interferon 
(IFN) response in a mechanism called ‘viral mimicry’ [4, 5]. By mimicking viral infections, HERVs could 
function as an ‘intrinsic adjuvant’, possibly sensitizing cancer cells for immune recognition [3]. Tumor-
associated reactivation of HERVs has been reported in cancer tissues [6], and HERVs may play a prominent 
role in cancer immunogenicity, either by activating the viral defense pathway (viral mimicry) [4, 5] or by 
forming a novel pool of tumor-associated antigens that can serve as T-cell targets on tumor cells (Table 1). 
The interactions between HERVs and the adaptive immune system could be important for exploiting HERVs 
as targets in anti-cancer immunotherapy. However, some HERV elements, the HERV-encoded Envelope 
(Env) proteins, have immunosuppressive properties that are important in fetomaternal tolerance [3] and 
the mechanism could potentially be used to shield tumor cells from the host’s immunological attacks [7]. In 
this review, we discuss how HERVs interact with the adaptive immune system with a particular focus on T-
cell responses.  In particular, CD8+ T-cell responses are of particular importance in the defense against viral 
infection, which HERV expression could mimic, and they are key mediators of cancer cell destruction in 
cancer immune therapy. For HERV annotations, the  revised nomenclature by Mayer et al. 2011 [1] was 
used in this review whenever the primary literature provided sufficient information to support the use of 
this nomenclature.  
ADAPTIVE IMMUNE RESPONSE TO HERVS 
The majority of HERVs have degenerated proviral genomes, which prevent transcription of their retroviral 
genes. Still, some HERVs have retained their open reading frames (ORFs) within the human genome with 
the potential to allow transcription and translation, and hence contribute their viral proteins to the human 
proteome [3]. While the level of HERV expression in healthy human tissues is limited [6], it may be induced 
during malignant transformation or due to epigenetic therapy. Since these proteins have retroviral origins, 
they may form antigens that can be recognized by T cells and B cells. Animal and human studies have 
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demonstrated both humoral and cell-mediated immune responses against ERV-antigens [8–10], which 
could indicate that immunological tolerance to HERVs is incomplete; however, these antigens’ thymic 
expression is still poorly understood, and consequently the level of tolerance towards such antigens 
remains to be determined.  
Presentation of HERV-derived antigens by the major histocompatibility complex (MHC) class I is of 
particular interest to determine the potential immune recognition of HERVs. CD8
+
 T cells specific for HERV-
derived epitopes have been isolated and expanded from the blood of patients with regressing renal cell 
carcinoma (RCC) following nonmyeloablative allogeneic hematopoietic stem cell transplantation. Such 
HERV-specific T cells mediated the killing of patient-derived tumor cells in vitro [11]. Rolland et al. 2006 
demonstrated that the ERVW Env could induce dendritic cell maturation through an innate immune 
mechanism, which resulted in a TH1-like immune response [12]. TH1 immune responses are important in the 
defense against viral infection, which is mimicked by HERV expression. In the literature, several specific 
CD8
+
 T-cell responses against HERV-derived antigens in cancer have been reported (Table 1), indicating the 
potential importance of HERVs as a target for cell-mediated cytotoxicity in anti-cancer immunotherapy. 
Intuitively, humoral immune responses would not be of great importance since HERV expression is 
intracellular; however, the retroviral Env proteins are transported to the cell surface and could serve as 
direct targets for humoral immune responses [10]. Antibody responses may also be driven by inflammatory 
cell death and uptake, and both humoral and cell-mediated immunity against the ERVK Env protein have 
been detected in breast cancer patients [10]. Antibody-mediated immune responses were also reported in 
ovarian cancer patients and reverse transcriptase activity was observed in the plasma of ovarian cancer 
patients [13]. To mount an antibody-driven immune response, either direct secretion of HERV antigens 
from tumor cells or uptake of dying tumor cells with HERV expression should take place [10]. In many cases, 
antibody immune responses are accompanied by a CD8
+
 T-cell response. The lytic potential of such T cells 
may explain the potential shedding of HERV antigens from dying tumor cells and the presence of reverse 
transcriptase activity in plasma, as observed in ovarian cancer patients [13]. In particular, antibody 
responses against the retroviral group-specific antigen (Gag) and Env proteins have been reported in the 
literature, which could indicate that these viral proteins are highly immunogenic. 
IMMUNE TOLERANCE TO HERVS 
HERV expression exhibits tissue specificity [6], which is determined mainly by epigenetic regulation and the 
availability of tissue-specific transcription factors [14]. Expression of HERVs in the thymus is not well 
described, though the intrathymic expression of HERVs is believed to be incomplete mainly due to 
epigenetic silencing [3]. It has been speculated that HERVs share strong similarities with exogenous 
retroviruses and therefore incomplete immunological tolerance could be necessary to defend against 
exogenous retroviral infections [3]; however, the basal expression of HERVs in healthy tissues [6, 15] could 
indicate the need for tolerance towards HERVs to avoid autoimmune responses. Hence, peripheral 
tolerance and ignorance mechanisms may play prominent roles in the control of HERV-specific T-cell 
recognition in healthy individuals [3]. HERV activation of innate receptors, which mimics viral infections, 
can potentially induce an inflammatory state, leading to the production and secretion of T-cell-activating 
chemokines and cytokines [4, 5, 16] and thereby bypass the potential immunological ignorant state.  CD8+ 
T-cell responses against HERV-derived antigens have been reported in the literature (Table 1), strongly 
indicating an incomplete clonal deletion of HERV-antigen-specific T cells in the thymus. Understanding the 
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differences in HERV expression in the thymus and peripheral tissues would be of great importance for the 
use of HERVs as immunotherapeutic targets. 
T-CELL RESPONSES AGAINST HERVS IN TUMORS 
Schiavetti et al. 2002 was the first to report a CD8+ T-cell response against an HERV-derived epitope in a 
melanoma patient. They identified the gene, ERVK3 (HERV-K MEL), that encodes the peptide sequence 
(MLAVISCAV) presented in HLA-A2 and verified CD8
+
 T-cell recognition of autologous tumor cells targeting 
this peptide-MHC complex. ERVK3-specific CD8+ T cells were found in two melanoma patients where the 
autologous tumor cell lines expressed ERVK3, but no ERVK3-specific CD8+ T cells were detected in the blood 
of three healthy individuals analyzed in parallel [17]. This study was followed by Rakoff-Nahoum et al. 2006 
who, in silico, predicted fifteen peptides from ERVK Gag for prevalent HLA alleles and divided these 
peptides into four pools for an initial screening of T-cell responses in individuals with seminoma. T-cell 
responses to the ERVK peptide pools were found in the peripheral blood mononuclear cells (PBMCs) of 
seminoma patients at a much higher frequency than in healthy controls [18]. Some cancer types seem to 
have high and preferential expression of certain HERVs; in RCC, ERVE-4 has been shown to be prominently 
and preferentially expressed in comparison to other tumor types and to normal tissues, where no 
expression is observed [6, 19]. The long-conserved ORFs in ERVE-4 env could indicate a retained capacity to 
produce partial Env proteins in RCC tumors [19]. In several studies, HERV-specific T-cell recognition was 
detected in RCC. From the ERVE-4 locus, four epitopes have been identified that give rise to specific 
cytotoxic T-cell responses [11, 19]. Of these, Cherkasova et al. 2016 show that three HLA-A0201 in silico-
predicted peptides from the putative ERVE-4 Env protein could expand CD8
+
 T cells in vitro. Takashi et al. 
2008 reported a regression of metastatic RCC in patients following nonmyeloablative allogeneic 
hematopoietic stem cell transplantation with the detection of tumor-reactive, donor-derived CD8+ T cells in 
the blood of the patients. With the use of cDNA cloning, they identified an epitope from ERVE-4 as 
responsible for the tumor-reactivity of the donor-derived CD8
+
 T cells [11]. T-cell recognition of HERVs has 
likewise been described in a few other cancer types. Mullins & Linnebacher 2012 demonstrated the 
presence of T cells that reacted to the ORF of ERVH-2 in patients with gastrointestinal cancers. ERVH-2 has 
previously been shown to be strongly expressed in a subset of gastrointestinal cancers while having low 
expression in other tumor types and healthy tissue. They further used 10 ERVH-2-derived peptides for the 
in vitro stimulation of T cells from healthy donors, and demonstrated the induction of ERVH-2-specific T 
cells capable of lysing a HLA-A0201 colorectal cancer cell line expressing ERVH-2 [20]. Also in breast cancer 
patients, T-cell responses against ERVK was demonstrated following stimulation of PBMCs with autologous 
dendritic cells pulsed with ERVK Env antigens. T-cell proliferation was observed together with cytokine 
secretion, i.e., IFN-γ, interleukin-2 (IL-2), IL-6, IL-8, and chemokine CXCL10, only in breast cancer patients, 
indicating the presence of ERVK Env T-cell recognition in response to disease. Moreover, T cells with lytic 
capacity toward ERVK Env antigen were found in breast cancer patients but not in healthy females [10]. 
Together, these studies summarized in Table 1 suggest that HERVs can be immunogenic and have the 
ability to activate adaptive T-cell responses capable of tumor cell recognition, particularly the env gene, 
which has been suggested to be highly immunogenic. This antigen could be a promising candidate for 
future immunotherapeutic strategies such as cancer vaccines; however, among the group of HERVs, there 
may be substantial differences in their biological effects, potential roles in immune sensitization, and ability 
to form an antigen reservoir. Early data point towards distinct features for the expression profiles of 
different HERVs [6], but these characteristics remain to be fully elucidated. 
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REACTIVATION OF HERVS IN CANCER 
Many studies have associated HERV expression with various cancer types, such as breast cancer [21, 22], 
melanoma [23–25], and kidney cancer [11, 19].  The elevated expression of distinct HERVs observed in 
cancer cell lines could indicate a potential oncogenic role of HERVs, but the causative involvement of HERVs 
in cancer remains controversial (review the potential oncogenic role of HERVs in Kassiotis 2014 [26]). 
A study by Rooney et al. 2015 mapped the 66 HERVs from Mayer et al. 2011 to RNA-sequencing (RNAseq) 
data from 18 different tumor types from The Cancer Genome Atlas (TCGA) and corresponding healthy 
tissue controls from the Genotype-Tissue Expression (GTEx) project and TCGA  [6]. By mapping the RNAseq 
data to the HERV transcripts, they demonstrated that numerous HERVs showed enhanced transcription in 
tumor tissues compared to healthy tissues. Out of the 66 HERV loci, they highlighted three HERV loci 
(ERVH-5, ERVH48-1, and ERVE-4) with minimal to undetectable transcription in normal tissues and highly 
elevated expression in certain tumor tissues. Hence, the authors characterized these as tumor-specific 
endogenous retroviruses [6]. ERVH-5 is especially prominently expressed in bladder, colorectal, head & 
neck, lung squamous, ovarian, stomach, and uterine cancers and ERVH48-1 is especially prominently 
expressed in bladder cancer and prostate cancer, whereas ERVE-4 can be found specifically in RCC. 
Interestingly, cytotoxic T-cell activity against ERVE-4 was previously reported in RCC [11, 19]. From the 
Rooney et al. 2015 data it can be deduced that distinct HERV loci exhibited tumor-associated rather than 
tumor-specific transcription, because basal HERV expression is observed in healthy tissue, depending on 
the HERV loci and tissue type [6, 15]. The Rooney et al. 2015 study is, to date, the most comprehensive 
analysis of HERV expression in different cancer tissues compared to healthy tissues. ERVE-4 expression in 
RCC is a well-described example of tumor-associated HERV expression. Inactivation of the tumor 
suppressor gene von Hippel-Lindau (VHL) results in the overexpression of hypoxia-inducible transcription 
factor-2α (HIF-2α). HIF-2α binds to HIF response elements, which are located in the 5'LTR of ERVE-4. This 
LTR was found to be hypomethylated in RCC tumors that expressed ERVE-4, compared to other tumors and 
normal tissues, indicating a tissue specific epigenetic regulation in RCC [27, 28]. Cancer-specific 
transcription factors can be important for tumor-associated expression, e.g., ERVK has been demonstrated 
to be activated by the melanoma-specific transcription factor (MITF-M) [14, 29]. ERVK LTRs are additionally 
susceptible to stimulation by hormones, and hence ERVK expression has been suggested to be relevant in 
cancers of hormone-regulated tissues [30].  
The tumor-associated expression of HERVs observed in cancer tissues has naturally given rise to one 
question: do HERVs have a causal role in the development of cancer or is their expression a byproduct of 
malignant cellular transformation, such as global DNA hypomethylation? Global DNA hypomethylation is a 
hallmark for malignant cellular transformation and could potentially be a major contributor to the 
oncogenic activation of HERVs [26]. As a result of the malignant transformation, the levels of HERV 
transcripts and proteins in human cancers are highly dysregulated compared to healthy tissues, where 
HERV expression is either low or absent [6]. HERV-encoded protein expression in human cancer specimens 
is summarized in Table 2. 
EXPLOITING HERV REACTIVATION IN CANCER IMMUNOTHERAPY 
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HERVs exhibit tumor-associated expression in cancer cells [6] and could potentially be a novel pool of 
tumor-associated antigens to be exploited as targets for anti-cancer immunotherapy (Table 2) [10]. 
Another attractive trait of HERVs is their retroviral origin, which can promote innate immune responses and 
result in an adjuvant-like behavior to potentially boost anti-tumor immunity [31]. The immunogenic 
potential of HERVs is further supported by reports of humoral and cell-mediated immunity in the literature 
[10, 19] (Table 1). However, immunotherapy targeting HERVs is still in its infancy, but preliminary steps are 
being taken to elucidate the potential of HERV antigens in immunotherapy. 
HERVS USED AS TARGETS IN MONOCLONAL ANTIBODY THERAPY  
ERVK Env expression has been detected at much higher levels in malignant breast cancer cell lines than in 
healthy breast cell lines [10]. Wang-Johanning et al. 2012 observed that breast cancer cell lines and human 
primary breast cancers have abundant levels of ERVK Env on their cell surfaces, which makes them ideal 
targets for antibody therapy (Figure 1) [32]. Monoclonal ERVK Env antibodies inhibited the growth and 
proliferation of breast cancer cells lines in vitro. Induction of apoptosis was also observed in breast cancer 
cells treated with monoclonal ERVK Env antibodies [32]. Mice bearing xenograft tumors showed 
significantly reduced growth upon treatment with monoclonal ERVK Env antibodies, compared to control 
experiments [32]. Taken together, such data indicate the potential of monoclonal ERVK Env antibodies as a 
novel immunotherapeutic agent for the treatment of breast cancer. Intriguingly, ERVK-positive breast 
tumors develop lymph node metastasis more frequently than ERVK-negative breast tumors. Although the 
exact mechanism for this effect is poorly understood, it has been suggested that ERVK expression may have 
prognostic relevance in metastatic breast cancer [32]. Interestingly, initial clinical studies with a humanized 
monoclonal antibody targeting HERV Env protein as a treatment for multiple sclerosis demonstrated a 
favorable safety profile with no induction of immunogenicity [33]. These results are promising for future 
clinical use of HERV-targeting monoclonal antibodies, although the potential therapeutic efficacy needs to 
be confirmed in more comprehensive clinical studies.  
HERVS USED IN CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY  
Adoptive cellular immunotherapy with chimeric antigen receptor (CAR)-expressing T cells targeting ERVK 
Env has been investigated for melanoma [34] and breast cancer [35] (Figure 1). Krishnamurthy et al. 2015 
reported a decrease in tumor burden in a murine metastatic melanoma model when mice were treated 
with ERVK Env-specific CAR T cells. In vitro, these CAR T cells exhibited the specific lysis of tumor cells 
expressing ERVK Env on their surfaces [34]. Zhou et al. 2015 demonstrated that ERVK Env-specific CAR T 
cells could reduce tumor growth and tumor weight in xenograft breast cancer murine models [35]. In vitro 
experiments showed that ERVK Env-specific CAR T cells exhibited a cytotoxic effect on breast cancer cells 
but not healthy breast tissue. The antitumor effect observed for ERVK Env-specific CAR T cells was 
significantly reduced in breast cancer cells treated with either control T cells or short hairpin RNA (shRNA) 
to induce the knockdown of ERVK Env [35]. Furthermore, multiple cytokines, including IFN-γ, Tumor 
Necrosis Factor-α (TNF-α), and IL-2, were detected in the culture media of breast cancer cell lines treated 
with ERVK Env-specific CAR T cells, suggesting T-cell-mediated lytic activity [35]. In this same study, a 
significant reduction or complete inhibition of metastasis development was observed in the liver, brain, 
lungs, and lymph nodes of murine models treated with ERVK Env-specific CAR T cells, compared to control T 
cells [35]. Interestingly, they observed that ERVK Env interacted with the p53 and RAS pathway, which 
could indicate an oncogenic effect of ERVK Env protein [35]. Together, these two studies show the promise 
D
ow
nloaded from
 https://academ
ic.oup.com
/annonc/advance-article-abstract/doi/10.1093/annonc/m
dy413/5100881 by D
TU
 Library - Technical Inform
ation C
enter of D
enm
ark user on 21 Septem
ber 2018
 7 
of CAR T cells targeting ERVK Env in treating melanoma and breast cancer, but further studies are needed 
to translate these results into clinical use [34]. 
HERV-DERIVED ANTIGENS AS VACCINATION TARGETS 
Prophylactic vaccination against HERV-derived antigens could potentially elicit long-lived T-cell responses, 
in an otherwise tolerant host, that could eliminate early malignancies [10]. Therapeutic vaccine strategies 
have been suggested for breast cancer, ovarian cancer, kidney cancer, and other tumors where HERV-
derived epitopes have been demonstrated to be processed and presented, forming targets for T-cell 
recognition [10, 13, 19]. To test the vaccination efficacy against cancer, Kraus et al. 2013 generated a 
recombinant vaccinia virus that expressed the ERVK Env protein and a syngeneic mouse tumor model that 
introduced ERVK Env expression in murine renal carcinoma cells (RLZ-HKenv cells) [36]. Intravenous 
injection of RLZ-HKenv cells into BALB/c mice resulted in the formation of pulmonary metastases, which 
could be prevented by a single administration of the vaccine [36]. A prophylactic strategy was also tested, 
which showed complete protection against tumor development when using the ERVK Env vaccination, 
compared to wild-type vaccinia virus [36]. Vaccinated mice exhibited cell-mediated cytotoxic activity 
against RLZ-HKenv cells, suggesting that T-cell-mediated tumor cell killing was induced by the vaccine [36]. 
Kraus et al. 2014 also demonstrated, with a similar study, that ERVK Gag could potentially be a valuable 
target for anti-cancer immunotherapy [2]. A potential concern of HERV-based vaccine treatment could be 
hazardous ERVK expression in, e.g., hematopoietic stem cells [2]. Sacha et al. 2012 investigated the safety 
of the vaccine strategy in rhesus macaques by immunization with simian endogenous retrovirus (SERV) Gag 
and Env proteins demonstrating expansion of polyfunctional T cells to both SERV proteins and induction of 
antibody responses to SERV Env protein; no adverse effects, including a lack of autoimmunity, were 
reported [9]. ERV antigen-based vaccines show potential as a safe immunotherapeutic option against 
cancer in preclinical animal models [9, 36]; however, clinical human studies are needed to test both the 
efficacy and safety of the vaccine and facilitate further therapeutic development. 
DNA HYPOMETHYLATING AGENTS AND IMMUNOTHERAPY COMBINATORY TREATMENTS 
Alleviating the epigenetic silencing of distinct HERV loci in various cancer types may result in the 
reactivation of HERVs in tumor tissues, and this may happen following the intrinsic hypomethylating profile 
seen in many tumors [6]. A similar phenomenon could be induced using DNA hypomethylating agents, such 
as DNA methyltransferase inhibitors (DNMTi), e.g., azacitidine, decitabine, or guadecitabine. Recently, 
Brocks et al. 2017 showed that DNMTi and histone deacetylase inhibitor (HDACi) treatment resulted in the 
induction of the de novo transcription of LTRs in cancer cell lines rather than altering the expression of 
canonical genes [37]. Ohtani et al. 2018 demonstrated an epigenetic switch from DNA methylation to 
histone silencing depending on the evolutionary age of LTRs. LTRs from evolutionarily young HERVs such as 
the ERVK family are predominately silenced by DNA methylation, whereas LTRs from intermediate age 
HERVs are silenced by histone modifications [38]. 
Treatment with DNMTis has been shown to increase HERV transcription, including HERV-derived double-
stranded RNA (dsRNA), in tumor cell lines [4, 5]. HERV-derived dsRNA can trigger the viral defense pathway 
through the MDA5-MAVS dsRNA recognition pathway, resulting in an interferon response that resembles 
that of a viral infection [4, 5]. Interestingly, Ohtani et al. 2018 observed an increase in histone silencing of 
LTRs following DNMTi therapy, which suggest that the epigenetic silencing of HERVs can be rescued by 
histone silencing. This rationalizes a synergistic effect of inhibition of both DNA methylation and histone 
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silencing modifications. Dual depletion by azacitidine and knockdown of specific histone modifying 
enzymes increased the expression of viral defense genes. This was probably due to activation of LTRs from 
young HERVs as knockdown of histone modifying enzymes alone did not upregulate viral defense genes, 
indicating that activation of LTRs from intermediate age HERVs is not sufficient to induce a viral mimicry 
response [38]. This viral mimicry can lead to increased antigen processing and presentation, secretion of 
immune-attracting chemokines, expression of interferon-stimulated genes, upregulation of Cancer Testis 
Antigens (CTAs), and upregulation of immune checkpoints (Programmed Death-ligand 1 (PD-L1) and 
Cytotoxic T cell-associated Protein 4 (CTLA-4))  [16, 37]. These characteristics may result in induced T-cell 
attraction, as observed upon viral infection, and the upregulation of CTLA-4 and PD-L1 upon treatment with 
DNMTis can lead to a sensitization toward treatment with immune checkpoint inhibitors (Figure 1) [39]. In 
addition, Programmed Death-1 (PD-1) expression on the surface of T cells has been shown to be 
upregulated following DNMTi therapy [40].   
RNAseq data from melanoma patients treated with CTLA-4 antibodies showed that the long-term benefit of 
immune checkpoint therapy correlates with high basal expression levels of the azacitidine-induced viral 
defense gene signature in tumor samples [4]. This finding was confirmed in a murine melanoma model, 
which showed that low doses of azacitidine sensitize tumors to treatment with CTLA-4 antibodies [4]. 
Additionally, a synergy of decitabine and CTLA-4 antibodies was observed in murine ovarian cancer models, 
where a low dose of decitabine resulted in the upregulation of chemokines that attract natural killer (NK) 
cells and CD8+ T cells. Combining epigenetic therapy with CTLA-4 antibody therapy promotes the 
differentiation of naïve T cells into effector T cells and enhances cytotoxic T-cell responses together with 
increased survival in mice models [41]. Treatment of epithelial ovarian cancer and non-small cell lung 
cancer cell lines with azacitidine resulted in increased surface expression of PD-L1 as an upstream 
consequence of activating the viral interferon response pathway [42, 43] and may additionally have a direct 
impact on PD-1 expression in T cells [40]. Although PD-L1 expression generally serves as a negative 
regulator for T-cell-mediated tumor recognition, this marker also reflects the inflammatory state and hence 
high expression of PD-L1 correlates with good responses to PD-1 antibody therapy [39]. The combination of 
epigenetic therapy and immunotherapy, such as immune checkpoint inhibitors, could potentially be of 
great clinical importance [39]. The ectopic expression of HERVs upon DMNTi treatment could potentially 
result in novel antigens being recognized by cytotoxic T cells and possibly contributing to an enhanced 
effect of the combinatory treatment [37]. This could be of great importance, specifically in cancer types 
with a low mutational burden. The combination of epigenetic therapy and therapeutic vaccine strategies or 
adoptive T-cell transfer that both target HERV-derived antigens could be of particular interest as future 
cancer therapy strategies.  
CONCLUDING REMARKS 
Immunotherapy against cancer relies on the tight association of target antigen expression in diseased 
tissue with none to minimal expression in healthy tissues [36], and consequently there is great interest and 
therapeutic potential in the identification of antigens with a distinct tumor-associated profile. Certain HERV 
groups or loci offer such tumor-associated properties [6], and their expression may be further induced 
through already marketed anti-cancer therapies, such as DNMTis. These characteristics, together with their 
retroviral origin and the incomplete tolerance, make them a promising target for future anti-cancer 
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immunotherapy. Different immunotherapeutic strategies have been applied to HERV-antigens in vitro and 
in vivo, e.g., monoclonal antibodies, prophylactic and therapeutic vaccination, CAR
+
 T cells, and epigenetic 
therapy combined with immune checkpoint inhibitors, which validate the great potential of HERV antigens. 
The combination of epigenetic drugs and immunotherapy is exciting for future cancer therapy, especially 
for cancer types with low mutational burden that respond poorly to immunotherapy or cancer types with 
poor responses to immune checkpoint inhibitor treatment [37]. More than 46 clinical studies are currently 
addressing the safety and efficacy of such combination therapies (Table 3 and Supplementary Table 1). 
These studies were retrieved from Clinicaltrials.gov by searching for the combination of DNMTis and 
immune checkpoint inhibitors treating cancer. In-depth analyses of tumor and immune cells from the 
patients enrolled in these trials will provide critical information regarding the mechanistic role of HERV 
expression and the following effects, in terms of both viral mimicry and the generation of tumor antigens. 
Additionally, future proteomic studies that reveal the natural expression characteristics and levels of 
thymic HERV expression will be important in the process of developing safe and efficient strategies for 
targeting HERV expression in tumors. Furthermore, the knowledge of T-cell recognition of HERVs is 
currently very limited. Only a few T-cell epitopes have been characterized in patient samples from a variety 
of cancers, and little is known about the expression of the different HERV families in various cancer types. 
Hence the extent of HERV - T cell recognition in cancer is not yet known, as well as the potential existence 
of immunological hotspots in the HERV-derived proteins that may be the most valuable for targeting. Thus, 
in-depth analyses of the immunological mechanisms and, in particular, the role of HERV-derived antigen 
presentation will hopefully shed light on the potential interaction between epigenetic drugs and 
immunotherapy in stimulating immune responses in cancer. 
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Figure 1: DNMTis alleviate the epigenetic repression of HERVs by removing DNA methylation, causing HERV 
dsRNA to activate innate immune pathway mimicking viral infections resulting in secretion of Interferons 
(IFN). Stimulation of Interferon-receptors (IFNR) activate JAK/STAT signaling and upregulate expression of 
chemokines, PD-L1, CTLA-4 and component of the antigen presentation pathway. Separately, distinct HERVs 
exhibit tumor-associated expression similar to tumor-associated antigens (TAA) and may serve as targets 
for T cell recognition. Additionally, HERV Envelop (Env) expression on the cell surface make it susceptible to 
targeting by monoclonal antibodies (mAb) or chimeric antigen receptor T cells (CART).  
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TABLES 
HERV Epitope Location HLA Cancer type Reference 
ERV-4 FLHKTSVREV 6q15 A0201 Renal clear cell carcinoma [19] 
 SLNITSCYV     
 LLLQIMRSFV     
 ATFLGSLTWK 6q15 A11 Renal clear cell carcinoma [11] 
      
ERVH-2 CLYPFSAFL Xp22.32 A0201 Colorectal cancer [20] 
 PLLSVSLPLL*     
 SLNFNSFHFL     
      
ERVK   A0201 Breast cancer [10] 
 FLQFKTWWI  A0201 Seminoma [18] 
      
ERVK3** MLAVISCAV 16 A2 Melanoma [17] 
Table 1: Cytotoxic T cell responses against HERV-derived epitopes reported in the literature. All the 
reported cytotoxic T cell responses are found in malignant tissues. *Minor response reported. **HERV-K 
MEL is an antigenic protein that is encoded by a short open reading frame from a processed ERVK3. 
 
 
Cancer type HERV protein Sample type Reference 
Breast cancer ERVK Env Tissue [10] 
 ERVK RT Tissue [51] 
 ERVW Env Cell line, tissue [52] 
    
Endometrial carcinoma ERVW Env Tissue [53] 
    
Gastrointestinal cancer ERVH-2 Env Cell line [20] 
    
Germ cell tumor ERVK Env Cell line [54, 55] 
 ERVK Gag Cell line, tissue [55–57] 
    
Lymphoma ERVK Env Plasma [58] 
 ERVK Gag Plasma [58] 
    
Melanoma ERVK Env Cell line, tissue [24, 59] 
 ERVK Gag Cell line, tissue [23] 
 ERVK Rec Cell line, tissue [23] 
    
Ovarian cancer ERVK Env Cell line, tissue [13, 60] 
    
Prostate cancer ERVK Gag Tissue [61] 
    
Renal cell carcinoma ERVE-4 Env Cell line [19] 
Table 2: Expression of HERV-encoded proteins detected in human cancers. Env: Envelope, Gag: Group-
specific antigen, RT: Reverse transcriptase 
 
 
 
Drug combination Conditions Phase NCT # 
Azacitidine: Atezolizumab Myelodysplastic Syndrome (MDS) I NCT02508870 
 Avelumab Acute Myeloid Leukemia (AML), B-Cell I, II, III NCT02953561, NCT03390296, 
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Lymphoma NCT02951156 
 Durvalumab MDS, Colorectal Carcinoma, Ovarian Cancer, 
Breast Cancer, AML, T-Cell Lymphoma, Head 
and Neck Cancer, Non-Small Cell Lung 
Carcinoma (NSCLC) 
I, II NCT02281084, NCT02811497, 
NCT02775903, NCT03161223, 
NCT03019003, NCT02117219, 
NCT02250326 
 Ipilimumab Leukemia, MDS II NCT02397720, NCT02530463  
 Nivolumab MDS, AML II, III NCT03092674 
 Pembrolizumab Pancreas Cancer, Colorectal Cancer, 
Melanoma, MDS, NSCLC, Head and Neck 
Cancer, Urothelial Carcinoma, AML, Epithelial 
Ovarian Cancer 
I, II NCT03264404, NCT03182894, 
NCT02260440, NCT02816021, 
NCT03094637, NCT02959437, 
NCT02845297, NCT02546986, 
NCT02900560, NCT02512172 
 Tremelimumab Head and Neck Cancer, MDS  I, II NCT03019003, NCT02117219 
     
Decitabine: Avelumab AML I NCT03395873 
 Ipilimumab MDS, AML I NCT02890329 
 Nivolumab NSCLC, MDS, AML, Leukemia I, II, III NCT02664181, NCT03358719, 
NCT03092674, NCT02599649, 
NCT02397720, NCT02530463, 
NCT01928576, NCT03259516  
 Pembrolizumab AML, T-Cell Lymphoma, NSCLC, Breast Cancer I, II NCT02996474, NCT03240211, 
NCT03233724, NCT02957968 
     
Guadecitabine: Atezolizumab Leukemia, MDS, AML, Fallopian Tube 
Carcinoma, Ovarian Carcinoma, Primary 
Peritoneal Carcinoma, Urothelial Carcinoma 
I, II NCT02935361, NCT03206047, 
NCT02892318, NCT03179943 
 Durvalumab Kidney Cancer, Clear Cell Renal Cell 
Carcinoma, Hepatocellular carcinoma, 
Cholangiocarcinoma, Pancreatic cancer, 
Small Cell Lung Cancer 
I, II NCT03308396, NCT03257761, 
NCT03085849 
 Ipilimumab Melanoma I NCT02608437 
 Pembrolizumab Lung Cancer, Fallopian Tube Carcinoma, 
Ovarian Carcinoma, Primary Peritoneal 
Carcinoma, Prostatic Cancer, NSCLC 
I NCT03220477, NCT02901899, 
NCT02998567 
 Tremelimumab Small Cell Lung Cancer I NCT03085849 
TOTAL: 46   
Table 3: Clinical studies investigating the potential benefits of combining immune checkpoint inhibitors and 
DNA methyltransferase inhibitors (DNMTi) in cancer treatment based on ClinicalTrials.gov. Following 
immune checkpoint inhibitors were included; Pembrolizumab (anti-PD1), Nivolumab (anti-PD1), 
Durvalumab (anti-PDL1), Atezolizumab (anti-PDL1), Avelumab (anti-PDL1), Tremelimumab (anti-CTLA4) and 
Ipilimumab (anti-CTLA4). Following DNMTis were included; Azacitidine, Decitabine and Guadecitabine. 
Search results from all combinations of the two groups in the field ‘Intervention/treatment’ (e.g. 
Nivolumab Azacitidine) were included in the table, if a combination treatment of immune checkpoint 
inhibitors and DNMTis was used to treat cancer. 
 
AML: Acute Myeloid Leukemia, MDS: Myelodysplastic Syndrome, NSCLC: Non-Small Cell Lung Carcinoma 
 
The table shown here is a comprised version of the search results, the full table is available in the 
supplementary data (Supplementary Table S1).   
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SUPPLEMENTARY DATA (CAN BE PUBLISHED ONLINE ONLY) 
 
Status* Title Conditions Drugs Phase NCT # 
R Study of Durvalumab and Guadecitabine in 
Advanced Kidney Cancer 
Advanced Kidney Cancer, 
Kidney Cancer, Clear Cell 
Renal Cell Carcinoma 
Guadecitabine, 
Durvalumab 
I, II NCT03308396 
R Guadecitabine and Durvalumab in Treating 
Patients with Advanced Liver, Pancreatic, 
Bile Duct, or Gallbladder Cancer 
Advanced liver cancer, 
Advanced pancreatic 
cancer, Advanced bile duct 
cancer, Advanced 
gallbladder cancer 
Durvalumab, 
Guadecitabine 
I NCT03257761 
R SGI-110 Plus Durvalumab/Tremelimumab in 
SCLC 
Extensive-stage Small Cell 
Lung Cancer 
Durvalumab, 
Tremelimumab, 
Guadecitabine 
I NCT03085849 
ANR Safety and Efficacy Study of CC-486 and 
Durvalumab in Subjects with 
Myelodysplastic Syndromes 
Myelodysplastic Syndrome 
(MDS) 
Oral Azacitidine, 
Durvalumab 
II NCT02281084 
R Study of Azacitidine and Durvalumab in 
Advanced Solid Tumors (METADUR) 
Microsatellite Stable 
Colorectal Carcinoma, 
Platinum Resistant 
Epithelial Ovarian Cancer 
Type II, Estrogen Receptor 
Positive and HER2 
Negative Breast Cancer 
Azacitidine, 
Durvalumab 
II NCT02811497 
ANR An Efficacy and Safety Study of Azacitidine 
Subcutaneous in Combination with 
Durvalumab (MEDI4736) in Previously 
Untreated Subjects with Higher-Risk 
Myelodysplastic Syndromes (MDS) or in 
Elderly Subjects with Acute Myeloid 
Leukemia (AML) 
Acute Myeloid Leukemia 
(AML), MDS 
Azacitidine, 
Durvalumab 
II NCT02775903 
R Durvalumab in Different Combinations with 
Pralatrexate, Romidepsin and Oral 5-
Azacitidine for Lymphoma 
T-Cell Lymphoma Durvalumab, 
Pralatrexate, 
Romidepsin, 
Azacitidine 
I, II NCT03161223 
R A Phase IB/II Study with Azacitidine, 
Durvalumab, and Tremelimumab in 
Recurrent and/or Metastatic Head and Neck 
Cancer Patients 
Head and Neck Cancer Azacitidine, 
Durvalumab, 
Tremelimumab 
I, II NCT03019003 
R Phase 1 Study to Evaluate MEDI4736 in 
Subjects with Myelodysplastic Syndrome 
MDS Durvalumab, 
Azacitidine, 
Tremelimumab 
I NCT02117219 
ANR Safety and Efficacy Study of Nab®-Paclitaxel 
With CC-486 or Nab®-Paclitaxel with 
Durvalumab, and Nab®-Paclitaxel 
Monotherapy as Second/Third-line 
Treatment for Advanced Non-Small Cell 
Lung Cancer (abound2L+) 
Non-Small Cell Lung 
Carcinoma (NSCLC) 
Oral Azacitidine, 
Duravalumab, nab-
paclitaxel IV 
II NCT02250326 
R Pharmacologically Rational EpigenetiC 
Immunotherapy for SEcond Line Therapy in 
Patients with Non-Small Cell Lung Cancer 
(PRECISE) 
NSCLC Nivolumab, Oral 
Decitabine, 
Tetrahydrouridine 
II NCT02664181 
R DEC-205/NY-ESO-1 Fusion Protein CDX-
1401, Poly ICLC, Decitabine, and Nivolumab 
in Treating Patients with Myelodysplastic 
Syndrome or Acute Myeloid Leukemia 
MDS, AML, Chronic 
Myelomonocytic Leukemia 
Nivolumab, Decitabine, 
DEC-205/NY-ESO-1 
Fusion Protein CDX-
1401, Poly ICLC    
I NCT03358719 
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R Azacitidine With or Without Nivolumab or 
Midostaurin, or Decitabine and Cytarabine 
Alone in Treating Older Patients with Newly 
Diagnosed Acute Myeloid Leukemia or High-
Risk Myelodysplastic Syndrome 
MDS, AML Azacitidine, Cytarabine, 
Decitabine, 
Midostaurin, 
Nivolumab 
II, III NCT03092674 
ANR Lirilumab and Nivolumab with 5-Azacitidine 
in Patients with Myelodysplastic Syndromes 
(MDS) 
Leukemia Lirilumab, Nivolumab, 
Azacitidine 
II NCT02599649 
R An Open-Label Phase II Study of Nivolumab 
(BMS-936558) in Combination With 5-
azacytidine (Vidaza) or Nivolumab With 
Ipilimumab in Combination With 5-
azacytidine for the Treatment of Patients 
with Refractory/ Relapsed Acute Myeloid 
Leukemia and Newly Diagnosed Older AML 
(>65 Years) Patients 
Leukemia Azacitidine, 
Nivolumab, Ipilimumab 
II NCT02397720 
R Nivolumab and Ipilimumab with 5-
azacitidine in Patients with Myelodysplastic 
Syndromes (MDS) 
Leukemia, MDS Nivolumab, 
Ipilimumab, Azacitidine 
II NCT02530463 
R Phase II Anti-PD1 Epigenetic Therapy Study 
in NSCLC. (NA_00084192) 
NSCLC Azacitidine, Entinostat, 
Nivolumab 
II NCT01928576 
R Nivolumab With Chemotherapy in 
Refractory MDS 
MDS Nivolumab, 
Azacitidine, 
Fludarabine, 
Cyclophosphamide, 
Cytarabine, all trans 
retinoic acid, Sildenafil, 
Melphalan 
I, II NCT03259516 
R Pembrolizumab (Immunotherapy Drug) in 
Combination with Guadecitabine and 
Mocetinostat (Epigenetic Drugs) for Patients 
with Advanced Lung Cancer 
Lung Cancer Pembrolizumab, 
Guadecitabine, 
Mocetinostat 
I NCT03220477 
R Guadecitabine and Pembrolizumab in 
Treating Patients with Recurrent Ovarian, 
Primary Peritoneal, or Fallopian Tube 
Cancer 
Recurrent Fallopian Tube 
Carcinoma, Recurrent 
Ovarian Carcinoma, 
Recurrent Primary 
Peritoneal Carcinoma 
Guadecitabine, 
Pembrolizumab 
II NCT02901899 
NYR Combination Study of Guadecitabine and 
Pembrolizumab. (HyPeR) 
Castration-Resistant 
Prostatic Cancer, NSCLC 
Guadecitabine, 
Pembrolizumab 
I NCT02998567 
R Pembrolizumab and Decitabine for 
Refractory or Relapsed Acute Myeloid 
Leukemia 
Relapsed AML Pembrolizumab, 
Decitabine 
I, II NCT02996474 
NYR Study of Pembrolizumab Combined with 
Decitabine and Pralatrexate in PTCL and 
CTCL 
Peripheral T cell 
lymphoma, Cutaneous T 
cell lymphoma 
Pembrolizumab, 
Pralatrexate, 
Decitabine 
I NCT03240211 
R The Immune Checkpoint Inhibitor 
Pembrolizumab in Combination with Oral 
Decitabine and Tetrahydrouridine as First-
Line Therapy for Inoperable, Locally 
Advanced or Metastatic Non-Small Cell Lung 
Cancer 
NSCLC Decitabine, 
Tetrahydrouridine, 
Pembrolizumab 
I, II NCT03233724 
R Neoadjuvant Pembrolizumab + Decitabine 
Followed by Std Neoadj Chemo for Locally 
Advanced HER2- Breast Cancer 
Locally Advanced HER2 
Negative Breast Cancer 
Doxorubicin, 
Cyclophosphamide, 
Paclitaxel, Carboplatin, 
Decitabine, 
Pembrolizumab 
II NCT02957968 
R Azacitidine and Pembrolizumab in 
Pancreatic Cancer 
Pancreas Cancer Pembrolizumab, 
Azacitidine 
II NCT03264404 
NYR Epacadostat in Combination with 
Pembrolizumab and Azacitidine in Subjects 
Metastatic Colorectal 
Cancer 
Pembrolizumab, 
Azacitidine, 
I, II NCT03182894 
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with Metastatic Colorectal Cancer Epacadostat 
ANR A Phase 2 Study of Pembrolizumab (MK-
3475) in Combination with Azacitidine in 
Subjects with Chemo-refractory Metastatic 
Colorectal Cancer 
Metastatic Colorectal 
Cancer 
Pembrolizumab, 
Azacitidine 
II NCT02260440 
R Study of Oral Azacitidine (CC-486) in 
Combination with Pembrolizumab (MK-
3475) in Patients with Metastatic Melanoma 
Melanoma and Other 
Malignant Neoplasms of 
Skin, Metastatic 
Melanoma 
Azacitidine, 
Pembrolizumab 
II NCT02816021 
R Azacitidine and Pembrolizumab for Patients 
with Myelodysplastic Syndrome (MDS) 
MDS Azacitidine, 
Pembrolizumab 
II NCT03094637 
ANR Azacitidine Combined with Pembrolizumab 
and Epacadostat in Subjects with Advanced 
Solid Tumors (ECHO-206) 
NSCLC, Microsatellite-
stable colorectal cancer, 
Head and neck squamous 
cell carcinoma, Urothelial 
carcinoma, Melanoma 
Azacitidine, 
Pembrolizumab, 
Epacadostat, 
INCB057643, 
INCB059872 
I, II NCT02959437 
R Phase 2 Study of Azacitidine in Combination 
with Pembrolizumab in Relapsed/Refractory 
Acute Myeloid Leukemia (AML) Patients and 
in Newly Diagnosed Older (≥65 Years) AML 
Patients 
AML Azacitidine, 
Pembrolizumab 
II NCT02845297 
ANR Safety and Efficacy Study of CC-486 With 
MK-3475 to Treat Locally Advanced or 
Metastatic Non-Small Cell Lung Cancer 
NSCLC Oral Azacitidine, 
Pembrolizumab,  
II NCT02546986 
R Study of Pembrolizumab With or Without 
CC-486 in Patients with Platinum-resistant 
Ovarian Cancer 
Epithelial Ovarian Cancer Oral Azacitidine, 
Pembrolizumab 
II NCT02900560 
R A Study of Enhancing Response to MK-3475 
in Advanced Colorectal Cancer 
Colorectal Cancer Oral Azacitidine, 
Pembrolizumab, 
Romidepsin  
I NCT02512172 
R Guadecitabine and Atezolizumab in Treating 
Patients with Advanced Myelodysplastic 
Syndrome or Chronic Myelomonocytic 
Leukemia That Is Refractory or Relapsed 
Chronic Myelomonocytic 
Leukemia, MDS, Recurrent 
AML with Myelodysplasia-
Related Changes 
Atezolizumab, 
Guadecitabine 
I, II NCT02935361 
S Atezolizumab, Guadecitabine, and CDX-
1401 Vaccine in Treating Patients with 
Recurrent Ovarian, Fallopian Tube, or 
Primary Peritoneal Cancer 
Recurrent Fallopian Tube 
Carcinoma, Recurrent 
Ovarian Carcinoma, 
Recurrent Primary 
Peritoneal Carcinoma 
Atezolizumab, 
Guadecitabine, DEC-
205/NY-ESO-1 Fusion 
Protein CDX-1401, Poly 
ICLC 
I, II NCT03206047 
R A Study Evaluating the Safety and 
Pharmacology of Atezolizumab 
Administered in Combination with 
Immunomodulatory Agents in Participants 
with Acute Myeloid Leukemia (AML) 
AML Atezolizumab, 
Guadecitabine 
I NCT02892318 
R Overcoming Chechkpoint Inhibitor 
Resistance with Epigenetic Therapy in 
Urothelial Cancer 
Urothelial Carcinoma Atezolizumab, 
Guadecitabine 
II NCT03179943 
S A Study of Atezolizumab Administered 
Alone or in Combination with Azacitidine in 
Participants with Myelodysplastic 
Syndromes 
MDS Atezolizumab, 
Azacitidine 
I NCT02508870 
R A Study Investigating SGI-110 in 
Combination with Ipilimumab in 
Unresectable or Metastatic Melanoma 
Patients (NIBIT-M4) 
Metastatic Melanoma Ipilimumab, 
Guadecitabine 
I NCT02608437 
R Ipilimumab and Decitabine in Treating 
Patients with Relapsed or Refractory 
Myelodysplastic Syndrome or Acute 
Myeloid Leukemia 
Relapsed or Refractory 
MDS, Relapsed or 
Refractory AML 
Ipilimumab, Decitabine I NCT02890329 
R Avelumab With Decitabine as First Line for AML Avelumab, Decitabine I NCT03395873 
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AML Treatment of Patients With AML, Who 
Are Unfit for Intensive Chemotherapy 
R Avelumab (antiPDL1) and Azacytidine in 
Acute Myeloid Leukemia (AML) 
AML Avelumab, Azacitidine I, II NCT02953561 
R Pfizer Immunotherapy Combinations for 
Acute Myeloid Leukemia (AML) Multi-Arm 
Study 1 
AML Avelumab, Azacitidine, 
Utomilumab, 
Gemtuzumab 
Ozogamicin, Glasdegib, 
PF-04518600 
II NCT03390296 
R Avelumab In Combination Regimens That 
Include an Immune Agonist, Epigenetic 
Modulator, CD20 Antagonist and/or 
Conventional Chemotherapy in Patients 
with Relapsed or Refractory Diffuse Large B-
cell Lymphoma (R/R DLBCL) (Javelin DLBCL) 
Diffuse Large B-Cell 
Lymphoma 
Avelumab, Azacitidine, 
Utomilumab, 
Rituximab, 
Bendamustine, 
Gemcitabine, 
Oxaliplatin 
III NCT02951156 
TOTAL 46 (7 ANR, 3 NYR, 34 R, 2 S)     
Supplementary Table S1: Clinical studies investigating the potential benefits of combining immune 
checkpoint inhibitors and DNA methyltransferase inhibitors (DNMTi) in cancer treatment based on 
ClinicalTrials.gov. Following immune checkpoint inhibitors were included; Pembrolizumab (anti-PD1), 
Nivolumab (anti-PD1), Durvalumab (anti-PDL1), Atezolizumab (anti-PDL1), Avelumab (anti-PDL1), 
Tremelimumab (anti-CTLA4) and Ipilimumab (anti-CTLA4). Following DNMTis were included; Azacitidine, 
Decitabine and Guadecitabine. Search results from all combinations of the two groups in the field 
‘Intervention/treatment’ (e.g. Nivolumab Azacitidine) were included in the table, if a combination 
treatment of immune checkpoint inhibitors and DNMTis was used to treat cancer. 
 
R: Recruiting, NYR: Not Yet Recruiting, ANR: Active Not Recruiting, S: Suspended, AML: Acute Myeloid 
Leukemia, MDS: Myelodysplastic Syndrome, NSCLC: Non-Small Cell Lung Carcinoma 
 
*Status of the clinical trials was last updated 08/21/18. 
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